InsiderTrades

Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2022-08-10 00:00:00 ET · period of report 2022-08-09 · accession 0000899243-22-028244 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-08-10 2022-08-09 VRTX Arbuckle Stuart A EVP, COO S - Sale+OE $300.67 -5,690 61.9K -8% -$1.71M
D 2022-08-10 2022-08-09 VRTX Arbuckle Stuart A EVP, COO M - OptEx $155.57 +1,926 66.7K +3% +$299.6K
D 2022-08-10 2022-08-09 VRTX Arbuckle Stuart A EVP, COO M - OptEx $0.00 -1,926 6,635 -22% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-08-09 S D 900 $301.42 60,996 D — — (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $301.42 (range $301.13 to $301.61).
2 Common Common Stock 2022-08-09 M A 1,926 $155.57 66,686 D — —
3 Common Common Stock 2022-08-09 S D 4,790 $300.53 61,896 D — — (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $300.53 (range $300.00 to $300.84).
4 Derivative Stock Option (Right to Buy) 2022-08-09 M D 1,926 $0.00 6,635 D $155.57 · — to 2028-02-05 1,926 Common Stock (F5) Fully vested.